Piracetam reduces oxidative stress and mitochondrial function impairment in an in vitro model of vascular dementia.
OGD
Oxidative stress
PI3K/Akt/mTOR axis
Piracetam
Vascular dementia (VaD)
Journal
Experimental brain research
ISSN: 1432-1106
Titre abrégé: Exp Brain Res
Pays: Germany
ID NLM: 0043312
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
received:
19
03
2024
accepted:
30
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
6
6
2024
Statut:
aheadofprint
Résumé
Vascular dementia (VaD) is the most common cause of dementia in older adults. Due to the lack of effective treatment options, there is an urgent need to find an effective pharmaceutical compound to combat VaD. Piracetam has been reported to improve impaired cognitive function in a variety of conditions in both human and animal models. However, the role and mechanism of Piracetam in VaD remain unclear. Therefore this study aimed to elucidate the effect of Piracetam on a cellular model of VaD in vitro. We found that Piracetam enhanced the growth of OGD-stimulated SH-SY5Y cells. In addition, Piracetam inhibited the oxidative stress of OGD-stimulated SH-SY5Y cells. Further, Piracetam improved mitochondrial function of OGD-stimulated SH-SY5Y cells. Mechanistically, Piracetam inhibited the PI3K/Akt/mTOR pathway in OGD-stimulated SH-SY5Y cells. Collectively, Piracetam improved oxidative stress and mitochondrial dysfunction of OGD-stimulated SH-SY5Y cells through PI3K/Akt/mTOR axis. Hence, Piracetam has the potential to serve as a promising drug of VaD.
Identifiants
pubmed: 38842755
doi: 10.1007/s00221-024-06868-x
pii: 10.1007/s00221-024-06868-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cohen PA, Zakharevich I, Gerona R (2020) Presence of Piracetam in Cognitive Enhancement Dietary supplements. JAMA Intern Med 180:458–459. https://doi.org/10.1001/jamainternmed.2019.5507
doi: 10.1001/jamainternmed.2019.5507
pubmed: 31764936
Dichgans M, Leys D (2017) Vascular cognitive impairment. Circ Res 120:573–591. https://doi.org/10.1161/CIRCRESAHA.116.308426
doi: 10.1161/CIRCRESAHA.116.308426
pubmed: 28154105
Du SQ, Wang XR, Xiao LY, Tu JF, Zhu W, He T, Liu CZ (2017) Molecular mechanisms of vascular dementia: what can be learned from animal models of chronic cerebral hypoperfusion? Mol Neurobiol. 54:3670–3682. https://doi.org/10.1007/s12035-016-9915-1
Guan T, Xiao Y, Xie X, Meng N, Qi Q, Xu J, Lv P (2023) Dulaglutide improves gliosis and suppresses Apoptosis/Autophagy through the PI3K/Akt/mTOR signaling pathway in vascular dementia rats. Neurochem Res 48:1561–1579. https://doi.org/10.1007/s11064-022-03853-0
doi: 10.1007/s11064-022-03853-0
pubmed: 36571662
Hall ED, Von Voigtlander PF (1987) Facilitatory effects of piracetam on excitability of motor nerve terminals and neuromuscular transmission. Neuropharmacology 26:1573–1579. https://doi.org/10.1016/0028-3908(87)90003-7
doi: 10.1016/0028-3908(87)90003-7
pubmed: 2829047
Hosoki S, Hansra GK, Jayasena T, Poljak A, Mather KA, Catts VS, Sachdev PS (2023) Molecular biomarkers for vascular cognitive impairment and dementia. Nat Rev Neurol 19:737–753. https://doi.org/10.1038/s41582-023-00884-1
doi: 10.1038/s41582-023-00884-1
pubmed: 37957261
Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Muller WE (2006) Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol 147:199–208. https://doi.org/10.1038/sj.bjp.0706459
doi: 10.1038/sj.bjp.0706459
pubmed: 16284628
Li X, Ren C, Li S, Han R, Gao J, Huang Q, Ji X (2017) Limb remote ischemic conditioning promotes myelination by upregulating PTEN/Akt/mTOR signaling activities after chronic cerebral hypoperfusion. Aging Dis 8:392–401. https://doi.org/10.14336/AD.2016.1227
doi: 10.14336/AD.2016.1227
pubmed: 28840054
pmcid: 5524802
Luan Y, Luan Y, Jiao Y, Liu H, Huang Z, Feng Q, Ren K (2023) Broadening Horizons: exploring mtDAMPs as a mechanism and potential intervention target in Cardiovascular diseases. Aging Dis. https://doi.org/10.14336/AD.2023.1130
doi: 10.14336/AD.2023.1130
pubmed: 38270118
pmcid: 10389826
Malykh AG, Sadaie MR (2010) Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 70:287–312. https://doi.org/10.2165/11319230-000000000-00000
doi: 10.2165/11319230-000000000-00000
pubmed: 20166767
Mindus P, Cronholm B, Levander SE, Schalling D (1976) Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand 54:150–160. https://doi.org/10.1111/j.1600-0447.1976.tb00107.x
doi: 10.1111/j.1600-0447.1976.tb00107.x
pubmed: 785952
Muley MM, Thakare VN, Patil RR, Bafna PA, Naik SR (2013) Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model. Life Sci 93:51–57. https://doi.org/10.1016/j.lfs.2013.05.020
doi: 10.1016/j.lfs.2013.05.020
pubmed: 23743171
Nasr M, Wahdan SA (2019) Neuroprotective effects of novel nanosystems simultaneously loaded with vinpocetine and piracetam after intranasal administration. Life Sci 226:117–129. https://doi.org/10.1016/j.lfs.2019.04.014
doi: 10.1016/j.lfs.2019.04.014
pubmed: 30981765
O’Brien JT, Thomas A (2015) Vascular dementia. Lancet 386:1698–1706. https://doi.org/10.1016/S0140-6736(15)00463-8
doi: 10.1016/S0140-6736(15)00463-8
pubmed: 26595643
Rajeev V, Fann DY, Dinh QN, Kim HA, De Silva TM, Lai MK, P, Arumugam TV (2022) Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. Theranostics 12:1639–1658. https://doi.org/10.7150/thno.68304
doi: 10.7150/thno.68304
pubmed: 35198062
pmcid: 8825579
Verma DK, Gupta S, Biswas J, Joshi N, Singh A, Gupta P, Singh S (2018) New therapeutic activity of metabolic enhancer piracetam in treatment of neurodegenerative disease: participation of caspase independent death factors, oxidative stress, inflammatory responses and apoptosis. Biochim Biophys Acta Mol Basis Dis 1864:2078–2096. https://doi.org/10.1016/j.bbadis.2018.03.014
doi: 10.1016/j.bbadis.2018.03.014
pubmed: 29551729
Wolters FJ, Ikram MA (2019) Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol 39:1542–1549. https://doi.org/10.1161/ATVBAHA.119.311908
doi: 10.1161/ATVBAHA.119.311908
pubmed: 31294622
Xiao H, Peng D, Guo YJE, J o G, O (2023) CENPF facilitates endometrial cancer cell progression through PI3K/AKT/mTOR pathway. Eur J Gynaecol Oncol 44:106–114
Xu P, Li M, Bai Y, Lu W, Ling X, Li W (2015) The effects of piracetam on heroin-induced CPP and neuronal apoptosis in rats. Drug Alcohol Depend 150:141–146. https://doi.org/10.1016/j.drugalcdep.2015.02.026
doi: 10.1016/j.drugalcdep.2015.02.026
pubmed: 25801591